文献-镇痛||A型毒素的镇痛缺点

文献-解热||A型毒效用以缠神经节迟滞治疗法多样各地区瘙痒syndrome

A型效用以缠神经节迟滞治疗法多样各地区瘙痒syndrome：一项随机测试

Max背景：Max

本科学研究旨在验证效通过不间断升高皮肤高温拉长缠神经迟滞不间断时间的论据。笔记进行了一项随机、双盲、对照测试，科学研究a型效治疗法多样各地区瘙痒syndrome患儿缠神经节迟滞的临床。

Max新方法：Max

选用75 IU A型效（效组成员）和发散小儿（对照组成员），对下肢多样各地区瘙痒syndrome患儿进行缠神经节迟滞。

主要结果是1个月底后迟滞侧足底与对侧足底的一般来说炎热变异。

次要结果是3个月底后的一般来说炎热变异以及瘙痒强度变异。

Max结果：Max

共有48名参与者（N=24/组成员）被随机分配。

效组成员的一般来说高温增加高于对照组成员（分别为1.0±1.3℃ vs. 0.1±0.8℃；差异：0.9℃[95%CI：0.3～1.5]；P=0.006）。

维系至术后3个月底，为1.1±0.8 ℃ vs.-0.2±1.2 ℃；P=0.009。

此外，与对照组成员相比，效组成员在1个月底（分别为（-2.2±1.0 vs.-1.0±1.6；P=0.003）和3个月底（分别为（-2.0±1.0 vs.-0.6±1.6；P=0.003）时的瘙痒强度显著降低。

未与效注射相关的严重不良意外事件。

Max结论：Max

在多样各地区瘙痒syndrome患儿当中，常用A型效进行缠神经节迟滞可使患足高温升高3个月底，并需用瘙痒。

Botulinum Toxin Type A for Lumbar Sympathetic GanglionBlock in Complex Regional Pain Syndrome: A Randomized Trial

Background: The present study was designed totest the hypothesis that botulinum toxin would prolong the duration of a lumbarsympathetic block measured through a sustained increase in skin temperature.The authors performed a randomized, double-blind, controlled trial to investigatethe clinical outcome of botulinum toxin type A for lumbar sympathetic ganglionblock in patients with complex regional pain syndrome.

Methods: Lumbar sympathetic ganglion block wasconducted in patients with lower-extremity complex regional pain syndrome using75 IU of botulinum toxin type A (botulinum toxin group) and local anesthetic(control group). The primary outcome was the change in the relative temperaturedifference on the blocked sole compared with the contralateral sole at 1postoperative month. The secondary outcomes were the 3-month changes inrelative temperature differences, as well as the pain intensity changes.

Results: A total of 48 participants (N = 24/group)were randomly assigned. The change in relative temperature increase was higherin the botulinum toxin group than in the control group (1.0°C ± 1.3 vs. 0.1°C ±0.8, respectively; difference: 0.9°C [95% CI, 0.3 to 1.5]; P = 0.006), whichwas maintained at 3 months (1.1°C ± 0.8 vs. -0.2°C ± 1.2, respectively; P =0.009). Moreover, pain intensity was greatly reduced in the botulinum toxingroup compared with the control group at 1 month (-2.2 ± 1.0 vs. -1.0 ± 1.6,respectively; P = 0.003) and 3 months (-2.0 ± 1.0 vs. -0.6 ± 1.6, respectively;P = 0.003). There were no severe adverse events pertinent to botulinum toxininjection.

Conclusions: In patients with complex regionalpain syndrome, lumbar sympathetic ganglion block using botulinum toxin type Aincreased the temperature of the affected foot for 3 months and also reducedthe pain.